AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29698824 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial morphing + health information
Number of subjects: 219
Study 29698824 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness + health information
Number of subjects: 219
Study 29698824 — intervention group
Group type: COMPARATOR
Intervention: Health information only
Number of subjects: 219
Study 26807682 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV+)
Number of subjects: 50
Study 26807682 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 50
Study 24849364 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline frontal cortex activity
Number of subjects: 13
Study 24849364 — intervention group
Group type: EXPERIMENTAL
Intervention: STN theta-delta activity
Number of subjects: 13
Study 23087401 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 768
Study 23087401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 768
Study 20564914 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients with T2D
Number of subjects: 1316
Study 20564914 — intervention group
Group type: COMPARATOR
Intervention: Asthmatic patients
Number of subjects: 1316
Study 20564914 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD concurrent with T2D
Number of subjects: 1316
Study 20564914 — intervention group
Group type: COMPARATOR
Intervention: T2D cohort
Number of subjects: 1316
Study 20564914 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD and T1D
Number of subjects: 1316
Study 18460663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pill containing 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12
Number of subjects: 5442
Study 18460663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5442
Study 16368822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg IV
Number of subjects: 40
Study 16368822 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 40
Study 12604743 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of older African American men to a cancer screening trial
Number of subjects: 34376
Study 10602739 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 27
Study 10602739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 27
Study 10602739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 27
Study 10602739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoroquinolones (general)
Number of subjects: 27
Study 10602739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-positive bacteria isolated
Number of subjects: 27
Study 8615305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA) with adjunctive balloon angioplasty
Number of subjects: 64
Study 8615305 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (PTCA)
Number of subjects: 64
Study 1730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine B (100 mg/kg per day by continuous 72‐hour subcutaneous infusions)
Number of subjects: 28
Study 1730079 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine B
Number of subjects: 28
Study 1730079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6397729 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-HTP (100 mg/day)
Number of subjects: 30
Study 6397729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30481393 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened mouthguard (2 mm palatal extension)
Number of subjects: 18
Study 30481393 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthguard (6 mm palatal extension)
Number of subjects: 18
Study 29529618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous regional administration (IORA) of 500 mg vancomycin
Number of subjects: 20
Study 29529618 — intervention group
Group type: COMPARATOR
Intervention: Systemic IV administration of 1 g vancomycin
Number of subjects: 20
Study 26399648 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV education for mothers
Number of subjects: 97
Study 26399648 — intervention group
Group type: COMPARATOR
Intervention: Diabetes education for mothers
Number of subjects: 97
Study 26399648 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level data
Number of subjects: 97
Study 24655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild right ventricular outflow tract obstruction (RVOTO) with a peak RVOT pressure gradient of 20-50 mmHg (n = 29)
Number of subjects: 85
Study 24655705 — intervention group
Group type: COMPARATOR
Intervention: Isolated pulmonary regurgitation (PR) with a peak RVOT pressure gradient <20 mmHg (n = 56)
Number of subjects: 85
Study 24655705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild RVOTO
Number of subjects: 85
Study 22459239 — intervention group
Group type: EXPERIMENTAL
Intervention: Inertial sensor-based feedback during training session
Number of subjects: 17
Study 22459239 — intervention group
Group type: COMPARATOR
Intervention: Baseline and evaluation sessions (without feedback)
Number of subjects: 17
Study 20197425 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA step‐up (100 microg of fluticasone plus 50 microg of a long‐acting beta‐agonist twice daily)
Number of subjects: 182
Study 20197425 — intervention group
Group type: EXPERIMENTAL
Intervention: LTRA step‐up (100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene‐receptor antagonist daily)
Number of subjects: 182
Study 20197425 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS step‐up (250 microg of fluticasone twice daily)
Number of subjects: 182
Study 20197425 — intervention group
Group type: COMPARATOR
Intervention: Composite of three outcomes (exacerbations, asthma‐control days, and forced expiratory volume in 1 second)
Number of subjects: 182
Study 18060963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy + PR (n = 87)
Number of subjects: 298
Study 18060963 — intervention group
Group type: COMPARATOR
Intervention: Sacrocolpopexy alone (n = 211)
Number of subjects: 298
Study 18060963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sacrocolpopexy + PR and sacrocolpopexy alone)
Number of subjects: 298
Study 16671418 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan analysis for contusion evolution
Number of subjects: 21
Study 16671418 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of perilesional edema on first CT scan
Number of subjects: 21
Study 16671418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of area of surrounding edema to area of hemorrhagic products on first CT
Number of subjects: 21
Study 12789628 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia
Number of subjects: 50
Study 12789628 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact anaesthesia
Number of subjects: 50
Study 10999881 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable plastic lined nappies
Number of subjects: 48
Study 10999881 — intervention group
Group type: COMPARATOR
Intervention: Cotton nappies
Number of subjects: 48
Study 8638960 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposure group
Number of subjects: 3
Study 8638960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower exposure group
Number of subjects: 3
Study 8638960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 1345826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-bore silicone catheter (23 G, 15 cm)
Number of subjects: 50
Study 1345826 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheter (20 G, 3.2 cm)
Number of subjects: 50
Study 6234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megavitamin therapy (3 g of niacinamide, 1.2 g of calcium pantothenate, 0.6 g of pyridoxine, and ascorbic acid)
Number of subjects: 41
Study 6234505 — intervention group
Group type: EXPERIMENTAL
Intervention: Megavitamin therapy
Number of subjects: 41
Study 6234505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31152740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg daily)
Number of subjects: 17598
Study 31152740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17598
Study 27746396 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided group
Number of subjects: 564
Study 27746396 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 564
Study 25594486 — intervention group
Group type: EXPERIMENTAL
Intervention: PASS Remedial Program (PREP) training (n=10)
Number of subjects: 20
Study 25594486 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 20
Study 23873118 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1, 0.15, and 0.15 mcg/kg)
Number of subjects: 64
Study 23873118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 64
Study 21989181 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-session Hypnosis Intervention
Number of subjects: 180
Study 21989181 — intervention group
Group type: COMPARATOR
Intervention: 5-session structured-attention control
Number of subjects: 180
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose (LD) followed by 75 mg/d maintenance dose (MD) for 10 days
Number of subjects: 35
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg LD followed by 10 mg/d MD for 10 days
Number of subjects: 35
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/d MD for 11 days
Number of subjects: 35
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: VN‐P2Y12 measurement
Number of subjects: 35
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA measurement
Number of subjects: 35
Study 18278193 — intervention group
Group type: EXPERIMENTAL
Intervention: VN‐P2Y12 device
Number of subjects: 35
Study 16817598 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious state induced by threat of shock
Number of subjects: 0
Study 16817598 — intervention group
Group type: COMPARATOR
Intervention: Neutral state (quiet sitting)
Number of subjects: 0
Study 15519006 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2442
Study 15519006 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2442
Study 10653105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone vacuum technique
Number of subjects: 40
Study 10653105 — intervention group
Group type: COMPARATOR
Intervention: Contemporary cementing technique (Control)
Number of subjects: 40
Study 10653105 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary cementing technique
Number of subjects: 40
Study 9100164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 19
Study 9100164 — intervention group
Group type: COMPARATOR
Intervention: Orthognathic surgery (historical comparison)
Number of subjects: 19
Study 1543847 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine positioning during PAC insertion
Number of subjects: 33
Study 1543847 — intervention group
Group type: COMPARATOR
Intervention: Right-side down positioning during PAC insertion
Number of subjects: 33
Study 3907603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oversized grafts
Number of subjects: 173
Study 3907603 — intervention group
Group type: COMPARATOR
Intervention: Same-sized grafts
Number of subjects: 173
Study 31143999 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 165
Study 31143999 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 165
Study 29502548 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (10 mg) administered orally
Number of subjects: 36
Study 29502548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27068138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve model M4 (High density porous polyethylene)
Number of subjects: 42
Study 27068138 — intervention group
Group type: COMPARATOR
Intervention: Ahmed glaucoma valve model S2 (polypropylene)
Number of subjects: 42
Study 25212234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg for 24 months
Number of subjects: 361
Study 25212234 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 24 months
Number of subjects: 361
Study 25212234 — intervention group
Group type: COMPARATOR
Intervention: Non-ACS patients
Number of subjects: 361
Study 22795340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 1001
Study 20601740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC) 25 g per day for 10 weeks
Number of subjects: 53
Study 20601740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) isocaloric per day for 10 weeks
Number of subjects: 53
Study 20601740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (BC)
Number of subjects: 53
Study 20601740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 53
Study 17954554 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Care (custody planning intervention)
Number of subjects: 157
Study 17954554 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 157
Study 16282947 — intervention group
Group type: EXPERIMENTAL
Intervention: palivizumab (Synagis) 15 mg/kg, 5 monthly doses
Number of subjects: 55
Study 16282947 — intervention group
Group type: EXPERIMENTAL
Intervention: palivizumab (Synagis)
Number of subjects: 55
Study 12016180 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher led intervention (single lesson on emergency contraception)
Number of subjects: 3974
Study 12016180 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3974
Study 10340686 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxapine
Number of subjects: 0
Study 10340686 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotic agents
Number of subjects: 0
Study 8535541 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil added to nifedipine SR
Number of subjects: 273
Study 8535541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol added to nifedipine SR
Number of subjects: 273
Study 8535541 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil after metoprolol
Number of subjects: 273
Study 8535541 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR monotherapy
Number of subjects: 273
Study 1966794 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH), subcutaneous injection once daily
Number of subjects: 70
Study 1966794 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection once daily
Number of subjects: 70
Study 345314 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 360
Study 345314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 360
Study 345314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 30305761 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological consultation (experimental group)
Number of subjects: 112
Study 30305761 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative information by a nurse (control group)
Number of subjects: 112
Study 29039325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 60
Study 29039325 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 60
Study 25664701 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants (test group)
Number of subjects: 30
Study 25664701 — intervention group
Group type: COMPARATOR
Intervention: Delayed loaded implants (control group)
Number of subjects: 30
Study 24361986 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality system based on Kinect for balance training
Number of subjects: 0
Study 24361986 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22036858 — intervention group
Group type: COMPARATOR
Intervention: Compliance with treatment guidelines (damage control, transfusions, mechanical ventilation)
Number of subjects: 0
Study 22036858 — intervention group
Group type: COMPARATOR
Intervention: Moderate deviations from guidelines
Number of subjects: 0
Study 22036858 — intervention group
Group type: COMPARATOR
Intervention: Noncompliance with tidal volume and plateau pressure targets within the ventilation protocol
Number of subjects: 0
Study 22036858 — intervention group
Group type: COMPARATOR
Intervention: Noncompliance with weaning guideline
Number of subjects: 0
Study 19285524 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-page follow-up postal questionnaire
Number of subjects: 1587
Study 19285524 — intervention group
Group type: COMPARATOR
Intervention: 3-page follow-up postal questionnaire
Number of subjects: 1587
Study 17326544 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-adjusting positive airway pressure (APAP)
Number of subjects: 29
Study 17326544 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 29
Study 17326544 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for device
Number of subjects: 29
Study 17326544 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 18 months of therapy
Number of subjects: 29
Study 16858169 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg/d orally for 7 days
Number of subjects: 44
Study 16858169 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/d orally for 7 days
Number of subjects: 44
Study 16858169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg orally as a single dose
Number of subjects: 44
Study 11927735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Number of subjects: 107
Study 11927735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 9485128 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 64
Study 8563868 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release mesalazine (1500 mg/day)
Number of subjects: 109
Study 8563868 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (3000 mg/day)
Number of subjects: 109
Study 2539714 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 or 40 mg once daily)
Number of subjects: 12
Study 2539714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 778569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydergot (1.0 mg i.m.)
Number of subjects: 100
Study 778569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31041805 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band training programme (twice a week for 8 weeks)
Number of subjects: 30
Study 31041805 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 30
Study 28583116 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF T-tau measured 1 year post-stroke
Number of subjects: 210
Study 26037632 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 ml beetroot juice (5.5 mmol nitrate)
Number of subjects: 40
Study 26037632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22817699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol patch (TP; 2 mg, once a day)
Number of subjects: 44
Study 22817699 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salmeterol (50 µg, twice a day)
Number of subjects: 44
Study 22817699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol patch (TP)
Number of subjects: 44
Study 22817699 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salmeterol
Number of subjects: 44
Study 22379796 — intervention group
Group type: EXPERIMENTAL
Intervention: OPP + PCIA
Number of subjects: 120
Study 22379796 — intervention group
Group type: COMPARATOR
Intervention: PCIA
Number of subjects: 120
Study 20108779 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil 10 mg daily + Bicyclol 150 mg daily for 48 weeks
Number of subjects: 91
Study 20108779 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg daily alone for 48 weeks
Number of subjects: 91
Study 16452737 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoDur 20 mg
Number of subjects: 168
Study 16452737 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoDur 30 mg
Number of subjects: 168
Study 16452737 — intervention group
Group type: COMPARATOR
Intervention: Sham epidural injection
Number of subjects: 168
Study 15283931 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) containing 2 mg 17‐beta estradiol plus 1 mg norethisterone acetate daily for 6 months
Number of subjects: 30
Study 15283931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 30
Study 12713610 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ornidazole vaginal ovules (VO)
Number of subjects: 100
Study 12713610 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ornidazole vaginal tablets (VT)
Number of subjects: 100
Study 10451129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg x kg(‐1) promethazine i.m. prior to discharge
Number of subjects: 95
Study 10451129 — intervention group
Group type: COMPARATOR
Intervention: Placebo i.m. prior to discharge
Number of subjects: 95
Study 7775172 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine nasal spray
Number of subjects: 206
Study 2322789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 day Haemoccult
Number of subjects: 35184
Study 2322789 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 day Haemoccult
Number of subjects: 35184
Study 7406099 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic telephone contact initiated by the Health Department
Number of subjects: 0
Study 7406099 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28917229 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 g peanut butter (PBG)
Number of subjects: 37
Study 28917229 — intervention group
Group type: COMPARATOR
Intervention: 16 g lard (LG)
Number of subjects: 37